Finance entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention 4D Medical, the most common co-covered peer. They are better corroborated than the beat average, carrying 5 original sources each against 2.8 for the same window.
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention 4D Medical, the most common co-covered peer. They are better corroborated than the beat average, carrying 5 original sources each against 2.8 for the same window. The 6 average consequence score is above the beat benchmark of 5.7 in the same window. US Food & Drug Administration appears in 1 tracked Finance story from February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 96 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering US Food & Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
Reporting Season Pressure
Difficult February reports for CSL and Sonic Healthcare extend index declines.
Anteris Funding
Anteris Technologies raises approximately $440 million for heart valve technology.
Nasdaq Biotech Peak
The index records a 30% annual gain, diverging from broader tech markets.
Record Funding Year
Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
ASX Healthcare Slump
The sector begins a calendar year decline of 25% led by major heavyweights.
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
US Food & Drug Administration is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
